CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has released a business update highlighting strong preliminary financial results for 2024 and the ongoing success of its ...

13, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals ... steatohepatitis (MASH), today announced an update on its business performance, including preliminary* fourth-quarter and year-end net ...

Equities researchers at Leerink Partnrs reduced their FY2026 earnings per share estimates for shares of Madrigal Pharmaceuticals in a note issued to investors on Wednesday, February 5th. Leerink ...

The Mets have a one-year agreement with infielder Nick Madrigal, the club announced. It’s reportedly a split deal that pays the Wasserman client $1.35MM in the majors, with another $500K available via ...

Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the thirteen analysts that are presently covering the stock, ...

Investors often closely monitor such transactions for insights into executive sentiment and potential impacts on stock performance. Madrigal Pharmaceuticals specializes in pharmaceutical ...

CEO Bill Sibold hailed 2024 as a "transformational year" for Madrigal Pharmaceuticals, but Wall Street isn't as enthusiastic about the company's sales results. CEO Bill Sibold hailed 2024 as a ...

The major league portion of the contract is worth $1.35 million, according to The Post’s Joel Sherman, and contains another $500,000 in performance bonuses. Madrigal, 27, spent the last three ...

The New York Mets added infield depth Friday, signing Nick Madrigal to a one-year split contract, per Joel Sherman of The New York Post. The deal is worth $1.35 million with up to $500,000 in ...

Looking to add to their infield depth, the New York Mets agreed to a one-year deal with veteran Nick Madrigal on Friday, league sources confirmed. The New York Post first reported the agreement.